{"pmid":32445664,"title":"COVID-19 as a cause of immune thrombocytopenia.","text":["COVID-19 as a cause of immune thrombocytopenia.","Med Mal Infect","Humbert, S","Razanamahery, J","Payet-Revest, C","Bouiller, K","Chirouze, C","32445664"],"journal":"Med Mal Infect","authors":["Humbert, S","Razanamahery, J","Payet-Revest, C","Bouiller, K","Chirouze, C"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445664","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.medmal.2020.05.003","keywords":["covid-19","sars-cov-2","immune thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667600475858403328,"score":9.490897,"similar":[{"pmid":32395217,"pmcid":"PMC7202345","title":"Covid-19 and Children with Immune Thrombocytopenia: Emerging Issues.","text":["Covid-19 and Children with Immune Thrombocytopenia: Emerging Issues.","Mediterr J Hematol Infect Dis","Lassandro, Giuseppe","Palladino, Valentina","Palmieri, Viviana Valeria","Amoruso, Anna","Del Vecchio, Giovanni Carlo","Giordano, Paola","32395217"],"journal":"Mediterr J Hematol Infect Dis","authors":["Lassandro, Giuseppe","Palladino, Valentina","Palmieri, Viviana Valeria","Amoruso, Anna","Del Vecchio, Giovanni Carlo","Giordano, Paola"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395217","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4084/MJHID.2020.028","keywords":["children","covid-19","immune thrombocytopenia"],"topics":["Prevention"],"weight":1,"_version_":1666627827864174592,"score":95.18306},{"pmid":32420612,"title":"COVID-19-associated immune thrombocytopenia.","text":["COVID-19-associated immune thrombocytopenia.","Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection.","Br J Haematol","Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G","32420612"],"abstract":["Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection."],"journal":"Br J Haematol","authors":["Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420612","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16850","locations":["Thrombocytopenia","Thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667254896710123520,"score":65.7522},{"pmid":32445584,"title":"Immune Thrombocytopenia during Pregnancy due to COVID-19.","text":["Immune Thrombocytopenia during Pregnancy due to COVID-19.","Am J Hematol","Tang, Man Wai","Nur, Erfan","Biemond, Bart J","32445584"],"journal":"Am J Hematol","authors":["Tang, Man Wai","Nur, Erfan","Biemond, Bart J"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445584","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/ajh.25877","topics":["Case Report"],"weight":1,"_version_":1667600475795488768,"score":60.19178},{"pmid":32439817,"title":"Immune Thrombocytopenia (ITP) in a SARS-CoV-2 Positive Pediatric Patient.","text":["Immune Thrombocytopenia (ITP) in a SARS-CoV-2 Positive Pediatric Patient.","Pediatrics","See Tsao, Hoi","M Chason, Hannah","M Fearon, Deirdre","32439817"],"journal":"Pediatrics","authors":["See Tsao, Hoi","M Chason, Hannah","M Fearon, Deirdre"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439817","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1542/peds.2020-1419","topics":["Case Report"],"weight":1,"_version_":1667523504843522048,"score":53.89387},{"pmid":32342677,"title":"Severe Thrombocytopenia in a Patient with COVID-19.","text":["Severe Thrombocytopenia in a Patient with COVID-19.","Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.","Infect Chemother","Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran","32342677"],"abstract":["Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered."],"journal":"Infect Chemother","authors":["Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342677","source":"PubMed","week":"202018|Apr 27 - May 03","keywords":["covid-19","ceftriaxone, levofloxacin","lopinavir/ritonavir","thrombocytopenia"],"locations":["Thrombocytopenia"],"e_drugs":["Ceftriaxone","lopinavir-ritonavir drug combination","Levofloxacin"],"topics":["Case Report"],"weight":1,"_version_":1666138495809224708,"score":48.65976}]}